Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*

AIMS: To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin ± sulfonylurea. METHODS: In this 24-week, randomized, double-blind, placebo-controlled, parallel-group, multicentre study, participants...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Seino, Y, Min, K W, Niemoeller, E, Takami, A
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2012
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3466411/
https://ncbi.nlm.nih.gov/pubmed/22564709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1463-1326.2012.01618.x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi